<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18315">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01904110</url>
  </required_header>
  <id_info>
    <org_study_id>HL_RSNM_401</org_study_id>
    <nct_id>NCT01904110</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women</brief_title>
  <official_title>For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women(Phase IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM
      group) versus Weekly Oral risedronate(Risenexsplus group) in Korean postmenopausal
      osteoporotic women(Phase IV)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM
      group) versus Weekly Oral risedronate(Risenexsplus group) with Vitamin D in compliance,
      improvement of vitaminD and BMD in Korean postmenopausal osteoporotic women(Phase IV)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The propotion of patients with 25(Oh)D level &lt;20mg/ml of 12 months</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of Bone Mineral Density(BMD) value</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of PTH(Parathyroid hormone value)</measure>
    <time_frame>6months,1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Compliance  - overall groups of Risenex plus vs Risenex M</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change of Bone Mineral Density(BMD) value[Time frame: 1 year] The change of PTH(Parathyroid hormone value) [Time frame:6months,1 year] The change of Compliance  - overall groups of Risenex plus vs Risenex M(2groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of 25(Oh)D level in patients.</measure>
    <time_frame>6months,1year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Risenex M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risenex Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate/Cholecalciferol combination(montly)</intervention_name>
    <description>once a month</description>
    <arm_group_label>Risenex M</arm_group_label>
    <arm_group_label>Risenex Plus</arm_group_label>
    <other_name>Risenex M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate/Cholecalciferol combination(weekly)</intervention_name>
    <description>once a week</description>
    <arm_group_label>Risenex Plus</arm_group_label>
    <other_name>Risenex Plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female osteoporosis patients over 19years of age(with menopause).

             Definition of osteporosis

               -  They had a BMD T-score -2.5 or less at mean Lumbar spine(L1~L4), Femoral neck or
                  total. Or evidence of at least one vertebral fracture.

             Definition of menopause(can be one of three condition)

               -  For 12months spontaneous amenorrhea

               -  For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating hormone)
                  is 40 mlIU/mL and over

               -  6weeks after bilateral ovariectomy whether hysterectomy of not

          2. Patients who can be treated with oral bisphosphonate drugs

          3. Patients who have adequate to be measured DXA(Dual energy x-ray absorptiometry)

          4. Patients who made a voluntary agreement after explanation of this study

          5. Patients who participated in clinical trial(HL_RSNP_401) must have taken the
             Risenexplus and finish the study for 12 months.

        Exclusion Criteria:

          1. Patients with esophagus disorder.

          2. Patients administered with osteoprosis therapy(except calcium,Vit.D medication)
             within previous 3 months

          3. Patients with serum calcium concentrations 8.0mg/dL under.

          4. Patients with severe nephropathy(serum creatinine&gt; doulble of normal level

          5. Patients with unable to sit upright or stand 30minutes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngki Min, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center Seoul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mi Yu</last_name>
    <phone>82-2-3489-6168</phone>
    <email>yumi@hanlim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunyoung Park</last_name>
    <phone>82-2-3489-6137</phone>
    <email>andy8686@hanlim.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunbi Cho</last_name>
      <phone>82-2-2-3410-1204</phone>
      <email>miineunbi.cho@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>Sunyoung Park</last_name>
      <phone>82-2-3489-6137</phone>
      <email>andy8686@hanlim.com</email>
    </contact_backup>
    <investigator>
      <last_name>Youngki Min, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risedronate,cholecalciferol,BMD,montly,weekly,compliance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Risedronic acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
